201 related articles for article (PubMed ID: 35569810)
1. DNA-gold nanoprobe-based integrated biosensing technology for non-invasive liquid biopsy of serum miRNA: A new frontier in prostate cancer diagnosis.
Kshirsagar P; Seshacharyulu P; Muniyan S; Rachagani S; Smith LM; Thompson C; Shah A; Mallya K; Kumar S; Jain M; Batra SK
Nanomedicine; 2022 Jul; 43():102566. PubMed ID: 35569810
[TBL] [Abstract][Full Text] [Related]
2. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
3. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
5. The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.
de Nóbrega M; Dos Reis MB; Pereira ÉR; de Souza MF; de Syllos Cólus IM
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2893-2910. PubMed ID: 35922694
[TBL] [Abstract][Full Text] [Related]
6. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis.
Barceló M; Castells M; Bassas L; Vigués F; Larriba S
Sci Rep; 2019 Sep; 9(1):13772. PubMed ID: 31551516
[TBL] [Abstract][Full Text] [Related]
7. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
[TBL] [Abstract][Full Text] [Related]
8. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
[TBL] [Abstract][Full Text] [Related]
9. Combination of Urinary MiR-501 and MiR-335 With Current Clinical Diagnostic Parameters as Potential Predictive Factors of Prostate Biopsy Outcome.
Juracek J; Madrzyk M; Trachtova K; Ruckova M; Bohosova J; Barth DA; Pichler M; Stanik M; Slaby O
Cancer Genomics Proteomics; 2023; 20(3):308-316. PubMed ID: 37093688
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer early diagnosis: circulating microRNA pairs potentially beyond single microRNAs upon 1231 serum samples.
Liu HP; Lai HM; Guo Z
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32607548
[TBL] [Abstract][Full Text] [Related]
11. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
[TBL] [Abstract][Full Text] [Related]
12. Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer.
Wang J; Ni J; Beretov J; Thompson J; Graham P; Li Y
Crit Rev Oncol Hematol; 2020 Jan; 145():102860. PubMed ID: 31874447
[TBL] [Abstract][Full Text] [Related]
13. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
Jin W; Fei X; Wang X; Chen F; Song Y
J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer.
Mao Z; Ji A; Yang K; He W; Hu Y; Zhang Q; Zhang D; Xie L
Medicine (Baltimore); 2018 Oct; 97(42):e12806. PubMed ID: 30334974
[TBL] [Abstract][Full Text] [Related]
15. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
Kurul NO; Ates F; Yilmaz I; Narli G; Yesildal C; Senkul T
Prostate; 2019 Jul; 79(10):1125-1132. PubMed ID: 31045265
[TBL] [Abstract][Full Text] [Related]
16. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics.
Wang H; Yang L; Mi Y; Wang Y; Ma C; Zhao J; Liu P; Gao Y; Li P
Contrast Media Mol Imaging; 2022; 2022():6094409. PubMed ID: 35935308
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients.
Gurbuz V; Kiliccioglu I; Dikmen AU; Bilen CY; Sozen S; Konac E
Gene; 2020 Oct; 758():144963. PubMed ID: 32683077
[TBL] [Abstract][Full Text] [Related]
19. Candidate diagnostic miRNAs that can detect cancer in prostate biopsy.
Paziewska A; Mikula M; Dabrowska M; Kulecka M; Goryca K; Antoniewicz A; Dobruch J; Borowka A; Rutkowski P; Ostrowski J
Prostate; 2018 Feb; 78(3):178-185. PubMed ID: 29226351
[TBL] [Abstract][Full Text] [Related]
20. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
